Last reviewed · How we verify
Shanchol vaccine
Shanchol is an oral, inactivated cholera vaccine that stimulates immune responses against Vibrio cholerae O1 and O139 antigens to prevent cholera infection.
Shanchol is an oral, inactivated cholera vaccine that stimulates immune responses against Vibrio cholerae O1 and O139 antigens to prevent cholera infection. Used for Prevention of cholera caused by Vibrio cholerae O1 and O139 in endemic and epidemic settings.
At a glance
| Generic name | Shanchol vaccine |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Drug class | Oral inactivated vaccine |
| Target | Vibrio cholerae O1 and O139 antigens; cholera toxin B subunit |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Shanchol contains killed whole-cell Vibrio cholerae bacteria combined with recombinant cholera toxin B subunit. When administered orally, it triggers mucosal and systemic immune responses, inducing antibodies and cellular immunity against cholera toxin and bacterial surface antigens. This immune priming protects against infection by the two major pathogenic serogroups of V. cholerae.
Approved indications
- Prevention of cholera caused by Vibrio cholerae O1 and O139 in endemic and epidemic settings
Common side effects
- Abdominal pain or discomfort
- Diarrhea
- Nausea
- Vomiting
- Headache
Key clinical trials
- Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi (NA)
- Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ (PHASE3)
- To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131) (PHASE3)
- Extended Dose Intervals With Oral Cholera Vaccine in Cameroon (PHASE2)
- A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131). (PHASE3)
- Immunological Characteristics of a Population at Risk of Cholera After Oral Cholera Vaccine (CHOVAXIM) (NA)
- Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine (PHASE3)
- Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shanchol vaccine CI brief — competitive landscape report
- Shanchol vaccine updates RSS · CI watch RSS
- International Centre for Diarrhoeal Disease Research, Bangladesh portfolio CI